The absence of selective modulators capable of attenuating PAR-2-driven inflammatory pathways while preserving essential homeostatic functions represents not merely a gap but a critical barrier impeding advancement in CRC therapeutics. Here, F2RL1 is linked to colorectal carcinoma.